Abstract 929P
Background
The incidence of Laryngeal Squamous Cell Carcinoma (LSCC) has increased over the past 30 years, presenting new challenges in the management of this disease. In response to these evolving needs, we developed a machine learning (ML) prognostic model to optimize the treatment strategies for patients diagnosed with advanced LSCC.
Methods
Data from 2000 to 2020 were obtained from the SEER database. Patients who were not diagnosed based on histology, previous history of cancer or other concurrent malignancies, or unknown data were excluded. The chi-square test was used to compare variables. The Kaplan-Meier estimator, log-rank test, and Cox regression analysis identified prognostic factors for overall survival (OS) and cancer-specific survival (CSS). We constructed prognostic models using ML algorithms to predict 5-year survival. The data were randomly divided into training (70 %) and validation (30 %) sets. A validation method incorporating the area under the curve (AUC) of the receiver operating characteristic curve was used to validate the accuracy and reliability of the ML models.
Results
A total of 7,350 patients were included: 2,689 with glottic (GC), 4,349 with supraglottic (SuGC), and 312 with subglottic (SG) cancers. The median patient age was 60 years. A total of 88.8% of the patients had a T3 and T4. The largest racial group was white, comprising 74.8% of the cases, and 21.1% of the cases were black. Most cases were stage IV AJCC (89.5%), and 41.4% of the patients had N2. Of the patients, 52% underwent total laryngectomy, which was the most common surgical procedure (39.1%). ML was used to identify the most important features of GC, including age, sex, and AJCC staging. Age and sex were considered as key factors for SuGC metastasis. For SC, the most important features identified were surgery combined with radiotherapy, sex, and surgery combined with chemoradiotherapy.
Conclusions
This study presents ML models tailored to three anatomical sites of LSCC. Key factors such as age and sex for GC and SuGC and treatment combinations for SG. These models underscore their utility in personalized medicine, enabling clinicians to customize treatment strategies based on individual characteristics and improve clinical outcomes.
Clinical trial identification
Editorial acknowledgement
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
907P - Biomarker analysis of the phase III KEYNOTE-040 study of pembrolizumab (pembro) versus methotrexate, docetaxel, or cetuximab (SOC) for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
Presenter: Denis Soulieres
Session: Poster session 03
909P - Immunoscore-IC predicts nivolumab efficacy as adjuvant treatment after salvage surgery in head and neck cancer squamous cell carcinoma: The ADJORL1 trial
Presenter: Alix Marhic
Session: Poster session 03
911P - Association of genomic landscape and plasma protein dynamic changes with clinical outcome in patients with R/M HNSCC treated with pembrolizumab with nab-paclitaxel and platinum
Presenter: Xinrui Chen
Session: Poster session 03
912P - Selection of personalized salvage treatments in advanced refractory head and neck squamous cell carcinomas via multi-omics tumor profiling
Presenter: Ramin Ajami
Session: Poster session 03
913P - Characterisation of genomic biomarkers of response to cetuximab versus cisplatin in concomitance with radiotherapy in locally advanced squamous head and neck cancer
Presenter: Juan Carlos Redondo González
Session: Poster session 03
914P - The landscape of somatic copy number alterations of head and neck squamous cell carcinoma across different anatomic sites
Presenter: Juan Carlos Redondo González
Session: Poster session 03
915P - Longer OS and RFS for CD3high/PD-L1+ head and neck squamous cell carcinoma (HNSCC) patients
Presenter: Simon Laban
Session: Poster session 03
916P - Deep spatial profiling of head and neck squamous cell carcinoma offers insights into the tumor microenvironment of hpv-stratified patients
Presenter: Abhishek Aggarwal
Session: Poster session 03